Aurobindo Pharma Ltd.’s ANDA 205835 for Meropenem for Injection was approved on 27 Mar. 2017 by US FDA.
AuroMedics, a subsidiary of Aurobindo, will commence marketing the product in April 2017.
AuroMedics, a subsidiary of Aurobindo, will commence marketing the product in April 2017.
The most significant brick and mortar addition is the erecting of new 67.000 square foot facility in East Windsor, NJ. It will feature a state-of-the-art warehousing and distribution which will allow us to better serve the needs of our valued customer partners. The facility will also be the home for increased research and scientific study
Aurobindo Pharma USA is in the midst of a major expansion to its U.S. footprint. Read More »
*Source: U.S. FDA.gov publication; ending December 2016
For the calendar year 2016, Aurobindo received 56 Abbreviated New Drug Approvals (ANDAs) Read More »